| Antimicrobial Agent | Susceptibility Profile | Clinical Interpretation |
|---|---|---|
| Amikacin | Sensitive | <=2 |
| Cefepime | Sensitive | 2 |
| Cefotaxime | Sensitive | 4 |
| Ceftazidime | Sensitive | 4 |
| Ceftriaxone | Sensitive | 8 |
| Ciprofloxacin | Sensitive | <=0.25 |
| Colistin | Intermediate | <0.125 |
| Doripenem | Sensitive | <=0.12 |
| Gentamicin | Sensitive | <=1 |
| Imipenem | Sensitive | 0.5 |
| Levofloxacin | Sensitive | <=0.12 |
| Meropenem | Resistant | 8 |
| Minocycline | Sensitive | <=1 |
| Piperacillin/Tazobactam | Sensitive | <=4 |
| Ticarcillin-clavulanic acid | Sensitive | <=8 |
| Tobramycin | Sensitive | 0.25 |
| Trimethoprim/Sulfamethoxazole | Sensitive | <=20 |
| Resistant Gene Track | Detection Methodology | NCBI Genome Accession |
|---|---|---|
| blaoxa51-like | PCR |